<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762485</url>
  </required_header>
  <id_info>
    <org_study_id>PGSDFYY 202101</org_study_id>
    <nct_id>NCT04762485</nct_id>
  </id_info>
  <brief_title>Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia</brief_title>
  <official_title>Humanized Chimeric Antigen Receptor T Cells Against CD7 for Refractory/Relapsed CD7+ Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective,open-label, single center and single arm phase 1/2 study to evaluate&#xD;
      the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors&#xD;
      treatment for patients with refractory/relapsed CD7 positive acute leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and&#xD;
      efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory acute leukemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events are evaluated with CTCAE V5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>ORR includes CR, CRi, MLFS and PR. Complete remission (CR)#Bone marrow blasts &lt;5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0x 10^9/L; platelet count &gt;100x10^9/L. CR with incomplete hematologic recovery (CRi)#All CR criteria except for residual neutropenia (&lt;1.0x10^9/L) or thrombocytopenia (&lt;100x10^9/L). Morphologic leukemia-free state (MLFS): Bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required. Partial remission (PR): All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse(CIR)</measure>
    <time_frame>2 years</time_frame>
    <description>time from the date of achievement of a remission until the date of relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the duration of CAR T-cells in vivo</measure>
    <time_frame>2 years</time_frame>
    <description>the time of CAR-T cells' persistence in blood and the copies of CAR-T cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>T Lymphoblastic Leukemia/Lymphoma</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>CD38 positive relapsed or refractory acute leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine: Humanized CD7 CAR-T cells Split intravenous infusion of CD7 CAR-T cells [dose escalating infusion of (0.5- 10)x10^6 CD7 CAR-T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humanized CD7 CAR-T cells</intervention_name>
    <description>Split intravenous infusion of CD7 CAR-T cells [dose escalating infusion of (0.5-10)x10^6 CD7 CAR-T cells/kg</description>
    <arm_group_label>CD38 positive relapsed or refractory acute leukemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed CD7 positive relapsed/refractory acute leukemia.&#xD;
&#xD;
          2. Age 12-65 years.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) score 0-2.&#xD;
&#xD;
          4. CD7 on leukemia is &gt;30% positive detected with flow cytometry.&#xD;
&#xD;
          5. Patients with left ventricular ejection fraction â‰¥ 0.5 by echocardiography or grade&#xD;
             I/II cardiovascular dysfunction according to the New York Heart Association&#xD;
             Classification.&#xD;
&#xD;
          6. Patients with aspartate aminotransferase or glutamic-pyruvic transaminase &gt; 3x upper&#xD;
             limit of normal or bilirubin &gt; 2.0 mg/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients are pregnant or lactating&#xD;
&#xD;
          2. Patients with congenital immunodeficiency.&#xD;
&#xD;
          3. Patients with central nervous system leukemia.&#xD;
&#xD;
          4. Patients with uncontrolled active infection.&#xD;
&#xD;
          5. Patients with active hepatitis B or hepatitis C infection.&#xD;
&#xD;
          6. Patients with HIV infection.&#xD;
&#xD;
          7. Patients with atrial or venous thrombosis or embolism.&#xD;
&#xD;
          8. Patients with myo-infarction or severe arrythmia in the recent 6 months.&#xD;
&#xD;
          9. Other comorbidities that investigators considered not suitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiaowen tang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiaowen tang, Ph.D</last_name>
    <phone>(0086)51267781856</phone>
    <email>xwtang1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Yang, Ph.D</last_name>
    <phone>(0086)18896802149</phone>
    <email>ylyh188@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>(Select)</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaowen tang, phd</last_name>
      <phone>(0086)51267781856</phone>
      <email>xwtang1020@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD7 Positive</keyword>
  <keyword>CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

